DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...

According to the American Lung Association, the ROS1 gene mutation occurs in about 1% to 2% of lung cancers and is more common in patients with little to no history of smoking. The AnHeart ...

Want to learn about a clinical trial targeting patients who have tumours with ALK or ROS1 gene alterations?' reads a recent tweet from @NovartisCancrUS, Novartis' Twitter channel dedicated to its ...

Human epidermal growth factor receptor 2 (HER2) The human epidermal growth factor receptor 2 (HER2) gene mutation is involved in 1% to 4% of NSCLCs. About 1% to 2% of NSCLCs have the ROS1 mutation.

Genetic testing helps determine whether any specific gene mutations are driving your ... However, a doctor may still prescribe if you have ROS1-positive lung cancer. This is known as off-label ...

However, sometimes the gene is erroneously turned on by fusing with other genes. This errant process, called ALK rearrangement, can lead to unchecked cell growth and cancer development. The ROS1 gene ...